Submission for OMB Review; Screening Tool for Unaccompanied Alien Children Program Staff and Visitors (New Collection), 53381-53382 [2020-19024]

Download as PDF 53381 Federal Register / Vol. 85, No. 168 / Friday, August 28, 2020 / Notices will be enrolled in the study. Drivers will have a debriefing session if a driver chooses to withdraw from the study early or upon completion of the 8month participation period. Drivers who have a valid Class-A commercial driver’s license (CDL) and work at the participating company in regional and long-haul operations for at least one year will be eligible for the study. A convenience sample of 180 eligible drivers will be recruited to participate in the study. The study sample will include approximately 90 regional and 90 long-haul drivers. There will be no required minimum number of female or minority drivers. Data will be collected during each phase: (1) In the application, drivers will be asked to provide their name and contact information (home address, telephone number, and email address) to allow contact from the research team regarding their eligibility for the study. (2) In the briefing session, drivers will be asked to complete the Background Questionnaire. (3) During the study, information collection will occur through several streams: (a) A real-time fatigue monitoring system installed in the participating driver’s vehicle; (b) Smart phone apps to collect data from a psychomotor vigilance test, the Karolinska Sleepiness Scale, a sleep log, a difficulty of drive scale, a degree of drive hazards scale, a fatigue scale, and a stress scale; (c) an electronic logging device which will record information about the driver’s hours of service and driving; (d) a wrist actigraphy device to collect data on driver sleep and wake times. Drivers will be asked to synchronize the actigraph with a smartphone app daily; (e) smartphone or web-based questionnaires including an Exercise and Food Consumption Questionnaire, the quality of life short form 36 version-2 questionnaire (SF– 36v2), Family Interactions Questionnaire, and Job Descriptive Index. These will be completed by drivers at four different intervals, including the beginning (1st week) and middle (2nd month) of the baseline phase, and the middle (5th month) and end (8th month) of the intervention phase; (f) A questionnaire to assess corporate practices and corporate safety climate will be given to managers at the participating carriers. These will be completed by managers at the beginning (1st week) of the study and end (8th month) of the intervention phase; and (g) During the field study, carriers will be asked to provide information concerning crashes and roadside violations occurring during each driver’s period of study participation. Administrative cost information (e.g., equipment, labor, etc.) will also be collected from the carrier to evaluate cost-benefit of the intervention. OMB approval is requested for two years. Participation is voluntary and there are no costs to respondents other than their time. The total estimated annualized burden is 5,278 hours. ESTIMATED ANNUALIZED BURDEN HOURS Form name Carrier Management ....................................... Participation Agreement ................................. Retrieval of Company Monthly Roadside Violations/Crash Reports. Retrieval of Company Administrative Costs .. Management Practice questionnaire (Time 1) Management Practice questionnaire (Time 2) Application to Participate ............................... Actigraph Training .......................................... Background Questionnaire ............................. Daily Smartphone Questions ......................... PVT ................................................................ Exercise and Food Consumption Questionnaire. SF–36v2 ......................................................... Family Interactions Questionnaire ................. Safety Climate Questionnaire ........................ Job Descriptive Index ..................................... Post-Study Questionnaire .............................. Phone Briefings .............................................. Drivers ............................................................. Jeffrey M. Zirger, Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention. [FR Doc. 2020–18994 Filed 8–27–20; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Submission for OMB Review; Screening Tool for Unaccompanied Alien Children Program Staff and Visitors (New Collection) Office of Refugee Resettlement, Administration for Children and Families, Health and Human Services (HHS). ACTION: Request for public comment. AGENCY: VerDate Sep<11>2014 17:16 Aug 27, 2020 Jkt 250001 PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 Number of responses per respondent Number of respondents Type of respondent Average burden per response (in hours) 1 1 1 8 1 90/60 1 5 5 150 90 90 90 90 90 16 1 1 1 1 1 720 720 4 2 45/60 45/60 12/60 10/60 45/60 1/60 3/60 20/60 90 90 90 90 90 90 4 4 4 4 1 8 30/60 15/60 10/60 30/60 1 6/60 The Office of Refugee Resettlement (ORR), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS), is proposing to continue use of a coronavirus (COVID–19) screening form for Unaccompanied Alien Children (UAC) program staff and visitors at ORR-funded programs. The form was originally approved under emergency approval for 6 months. ACF is requesting a 3-year extension of this information collection. DATES: Comments due within 30 days of publication. OMB is required to make a decision concerning the collection of SUMMARY: E:\FR\FM\28AUN1.SGM 28AUN1 53382 Federal Register / Vol. 85, No. 168 / Friday, August 28, 2020 / Notices information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this ADDRESSES: notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. SUPPLEMENTARY INFORMATION: Description: The COVID–19 risk questionnaire asks participants whether or not they display COVID–19 symptoms, whether or not they have had close contact with individuals known to test positive for COVID–19, and whether or not they have been tested for COVID–19. The questionnaire also requests temperature checks on individuals. This will help to reduce possible exposure to the virus and help protect the health and safety of both UAC and program staff. Respondents: Staff and visitors at UAC program sites. ANNUAL BURDEN ESTIMATES Total number of respondents Instrument UAC COVID–19 Risk Questionnaire ............................................................... Authority: 6 U.S.C. 279(b)(1)(B);(E). Emily Ball Jabbour, ACF/OPRE Certifying Officer. [FR Doc. 2020–19024 Filed 8–27–20; 8:45 am] BILLING CODE 4184–45–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2020–N–0008] Patient Engagement Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing a forthcoming public advisory committee meeting of the Patient Engagement Advisory Committee. The general function of the committee is to provide advice to the Commissioner, or designee, on complex issues relating to medical devices, the regulation of devices, and their use by patients. The meeting will be open to the public. DATES: The meeting will take place virtually on October 22, 2020, from 10 a.m. Eastern Time to 5 p.m. Eastern Time. ADDRESSES: Please note that due to the impact of this COVID–19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. Answers to commonly asked questions about FDA advisory committee meetings may be accessed at: https:// www.fda.gov/AdvisoryCommittees/ AboutAdvisoryCommittees/ ucm408555.htm. Information on how to access the webcast will be made available no later SUMMARY: VerDate Sep<11>2014 17:16 Aug 27, 2020 Jkt 250001 15,000 than 2 business days prior to the meeting at www.fdalive.com/PEAC. FOR FURTHER INFORMATION CONTACT: Letise Williams, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave. Bldg. 66, Rm. 5441, Silver Spring, MD 20993–0002, letise.williams@ fda.hhs.gov, 301–796–8398, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s website at https:// www.fda.gov/advisory-committees and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications. SUPPLEMENTARY INFORMATION: Agenda: The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. On October 22, 2020, the committee will discuss and make recommendations on the topic ‘‘Artificial Intelligence (AI) and Machine Learning (ML) in Medical Devices.’’ Specifically, we will discuss the composition of the datasets on which the software ‘‘learns’’, components of the device information shared with patients, and factors that impact patient trust in the technology. Large clinical datasets are used to train and improve AI/ML algorithms, allowing transformational improvements in the diagnosis, clinical decision making, and treatment of patients. Devices using AI/ML technology will transform healthcare delivery by increasing efficiency of key processes in the treatment of patients. PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 Annual responses per respondent 260 Average burden hours per response .033 Annual burden hours 128,700 Health products powered by AI/ML are streaming into our lives, from virtual doctor apps to wearable sensors and drugstore chatbots to algorithms for detecting cancer in mammography and interpretations of chest X rays. Despite the rapid advancement and integration, AI/ML systems may have algorithmic biases, limited generalizability, and lack transparency in their assumptions based on potential limitations of training datasets. The recommendations provided by the committee will address the importance of including various demographic groups in AI/ML algorithm development. The recommendations will also address the impact of the user interface and transparency including what information and how the information about the devices could be communicated to foster patient trust in the AI/ML devices. FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available on FDA’s website at the time of the advisory committee meeting, and the background material will be posted on FDA’s website after the meeting. Background materials will be available at https:// www.fda.gov/advisory-committees/ committees-and-meeting-materials/ patient-engagement-advisorycommittee. Select the link for the 2020 Meeting Materials. The meeting will include slide presentations with audio components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Oral presentations E:\FR\FM\28AUN1.SGM 28AUN1

Agencies

[Federal Register Volume 85, Number 168 (Friday, August 28, 2020)]
[Notices]
[Pages 53381-53382]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-19024]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families


Submission for OMB Review; Screening Tool for Unaccompanied Alien 
Children Program Staff and Visitors (New Collection)

AGENCY: Office of Refugee Resettlement, Administration for Children and 
Families, Health and Human Services (HHS).

ACTION: Request for public comment.

-----------------------------------------------------------------------

SUMMARY: The Office of Refugee Resettlement (ORR), Administration for 
Children and Families (ACF), U.S. Department of Health and Human 
Services (HHS), is proposing to continue use of a coronavirus (COVID-
19) screening form for Unaccompanied Alien Children (UAC) program staff 
and visitors at ORR-funded programs. The form was originally approved 
under emergency approval for 6 months. ACF is requesting a 3-year 
extension of this information collection.

DATES: Comments due within 30 days of publication. OMB is required to 
make a decision concerning the collection of

[[Page 53382]]

information between 30 and 60 days after publication of this document 
in the Federal Register. Therefore, a comment is best assured of having 
its full effect if OMB receives it within 30 days of publication.

ADDRESSES: Written comments and recommendations for the proposed 
information collection should be sent within 30 days of publication of 
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular 
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function.

SUPPLEMENTARY INFORMATION:
    Description: The COVID-19 risk questionnaire asks participants 
whether or not they display COVID-19 symptoms, whether or not they have 
had close contact with individuals known to test positive for COVID-19, 
and whether or not they have been tested for COVID-19. The 
questionnaire also requests temperature checks on individuals. This 
will help to reduce possible exposure to the virus and help protect the 
health and safety of both UAC and program staff.
    Respondents: Staff and visitors at UAC program sites.

                                             Annual Burden Estimates
----------------------------------------------------------------------------------------------------------------
                                                   Total  number      Annual          Average
                   Instrument                           of         responses per   burden hours    Annual burden
                                                    respondents     respondent     per response        hours
----------------------------------------------------------------------------------------------------------------
UAC COVID-19 Risk Questionnaire.................          15,000             260            .033         128,700
----------------------------------------------------------------------------------------------------------------


    Authority: 6 U.S.C. 279(b)(1)(B);(E).

Emily Ball Jabbour,
ACF/OPRE Certifying Officer.
[FR Doc. 2020-19024 Filed 8-27-20; 8:45 am]
BILLING CODE 4184-45-P